EVA Study (ESHRE / VCUAM / ASRM)

Recruiting

Conditions: GENITALEFEHLBILDUNGE

Registration Number: DRKS00025001

Lead Sponsor: niversitätsklinik für Gynäkologie,Geburtshilfe und gynäkologischer Endokrinologie, Kepleruniversitätsklinikum Johannes Kepler Universität Linz

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 150

Inclusion Criteria

Women with corrected or uncorrected femal genital malformations.

Exclusion Criteria

missing agreement

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Practicability of the three common classifications in daily routine

Secondary Outcome Measures

Name	Time	Method

Related Trials

Studying the effect of (music therapy) Raga Bageshri in patients prone to be diabetic (Prediabetes) comparing with previously treated prediabetic patient

Phase 1

Sneha Santosh Banchhade

Updated 8/19/2024

A PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BAL8557 VERSUS A CASPOFUNGIN FOLLOWED BY VORICONAZOLE REGIMEN IN THE TREATMENT OF CANDIDEMIA AND OTHER INVASIVE CANDIDA INFECTIONS

ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

Updated 11/16/2015

Haemodynamic derangements during laryngoscopy using different intubating devices

Phase 1

Department of Anesthesiology and Critical Care

Updated 11/24/2021

COMPARATIVE, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF L-743,872 VS AMPHOTERICIN B IN THE TREATMENT OF CANDIDA ESOPHAGILITIS INFECTIONS IN ADULTS

Not Applicable

MERCK SHARP & DOHME PERU S.R.L.,

Updated 9/4/2023

An Open-Label Trial to look at the long-term safety and effectiveness of Brivaracetam used in addition to the subjects main treatment in subjects aged 16 years or older with epilepsy

Phase 1

CB Pharma SA

Updated 8/2/2021

An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating partial onset seizures for a long period of time in patients with epilepsy (=16 years to 80 years)

Phase 1

CB BioSciences INC.

Updated 11/12/2018

An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating partial onset seizures for a long period of time in patients with epilepsy (=16 years to 80 years)

Phase 1

CB BIOSCIENCES, INC.

Updated 6/30/2019

An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating seizures for a long period of time in patients with epilepsy (aged 16 years or older)

Phase 1

CB BIOSCIENCES, INC.

Updated 6/30/2019

AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH PARTIAL ONSET SEIZURES - ND

Phase 1

SCHWARZ BIOSCIENCES, INC A member of the UCB Group of Companies

Updated 11/23/2020

An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating partial onset seizures for a long period of time in patients with epilepsy (=16 years to 80 years)

Phase 1

CB BIOSCIENCES, INC.

Updated 6/30/2019

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy